Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template

被引:94
作者
Hunt, JT
Mitt, T
Borzilleri, R
Gullo-Brown, J
Fargnoli, J
Fink, B
Han, WC
Mortillo, S
Vite, G
Wautlet, B
Wong, T
Yu, CA
Zheng, XP
Bhide, R
机构
[1] Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Pharmaceut Res Inst, Oncol Drug Discovery, Princeton, NJ 08543 USA
关键词
D O I
10.1021/jm049892u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.
引用
收藏
页码:4054 / 4059
页数:6
相关论文
共 16 条
[1]   Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].
Barker, AJ ;
Gibson, KH ;
Grundy, W ;
Godfrey, AA ;
Barlow, JJ ;
Healy, MP ;
Woodburn, JR ;
Ashton, SE ;
Curry, BJ ;
Scarlett, L ;
Henthorn, L ;
Richards, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914
[2]   Protein kinase inhibitors: emerging pharmacophores 1997-2000 [J].
Dumas, J .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (03) :405-429
[3]  
FRY DW, 1994, SCIENCE, P265
[4]  
García-Echeverría C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.0.CO
[5]  
2-2
[6]   Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors [J].
Hennequin, LF ;
Thomas, AP ;
Johnstone, C ;
Stokes, ESE ;
Plé, PA ;
Lohmann, JJM ;
Ogilvie, DJ ;
Dukes, M ;
Wedge, SR ;
Curwen, JO ;
Kendrew, J ;
Lambert-van der Brempt, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) :5369-5389
[7]   Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors [J].
Hennequin, LF ;
Stokes, ESE ;
Thomas, AP ;
Johnstone, C ;
Plé, PA ;
Ogilvie, DJ ;
Dukes, M ;
Wedge, SR ;
Kendrew, J ;
Curwen, JO .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) :1300-1312
[8]  
Kim TE, 2003, IDRUGS, V6, P886
[9]   Potent and selective inhibitors of PDGF receptor phosphorylation.: 2.: Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives [J].
Matsuno, K ;
Nakajima, T ;
Ichimura, M ;
Giese, NA ;
Yu, JC ;
Lokker, NA ;
Ushiki, J ;
Ide, SI ;
Oda, S ;
Nomoto, Y .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) :4513-4523
[10]  
Moyer JD, 1997, CANCER RES, V57, P4838